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Lopinavir-ritonavir is frequently prescribed to HIV-1-infected women during pregnancy. Decreased lopinavir exposure has been
reported during pregnancy, but the clinical significance of this reduction is uncertain. This analysis aimed to evaluate the need
for lopinavir dose adjustment during pregnancy. We conducted a population pharmacokinetic analysis of lopinavir and ritona-
vir concentrations collected from 84 pregnant and 595 nonpregnant treatment-naive and -experienced HIV-1-infected subjects
enrolled in six clinical studies. Lopinavir-ritonavir doses in the studies ranged between 400/100 and 600/150 mg twice daily. In
addition, linear mixed-effect analysis was used to compare the area under the concentration-time curve from 0 to 12 h (AUC0–12)
and concentration prior to dosing (Cpredose) in pregnant women and nonpregnant subjects. The relationship between lopinavir
exposure and virologic suppression in pregnant women and nonpregnant subjects was evaluated. Population pharmacokinetic
analysis estimated 17% higher lopinavir clearance in pregnant women than in nonpregnant subjects. Lopinavir clearance values
postpartumwere 26.4% and 37.1% lower than in nonpregnant subjects and pregnant women, respectively. As the tablet formu-
lation was estimated to be 20%more bioavailable than the capsule formulation, no statistically significant differences between
lopinavir exposure in pregnant women receiving the tablet formulation and nonpregnant subjects receiving the capsule formu-
lation were identified. In the range of lopinavir AUC0–12 or Cpredose values observed in the third trimester, there was no correla-
tion between lopinavir exposure and viral load or proportion of subjects with virologic suppression. Similar efficacy was ob-
served between pregnant women and nonpregnant subjects receiving lopinavir-ritonavir at 400/100 mg twice daily. The
pharmacokinetic and pharmacodynamic results support the use of a lopinavir-ritonavir 400/100-mg twice-daily dose during
pregnancy.
The use of combination antiretroviral therapy (cART) is recom-mended in all pregnantwomenwithHIV infection for preven-
tion of perinatal transmission as well as for maternal health. Such
use has resulted in a significant reduction of perinatal transmis-
sion from 25% to 0–3.6% (1, 2). Treatment guidelines include the
use of protease inhibitors in combination with two nucleoside
reverse transcriptase inhibitors (NRTIs) (3–7).
Lopinavir (LPV) is a peptidomimetic HIV type 1 (HIV-1) pro-
tease inhibitor. When LPV is coadministered with low-dose
ritonavir (RTV), which acts as a pharmacokinetic enhancer by
blocking the cytochrome P450 3A (CYP3A)-mediated metabo-
lism of LPV, serum levels of LPV are significantly increased, and
half-life is prolonged. The high LPV exposures achieved with co-
formulated lopinavir-ritonavir (LPV/r) have the advantage of
providing a pharmacologic barrier to the emergence of HIV-1
viral resistance in patients with wild-type virus, as well as en-
hanced activity against some forms of drug-resistant HIV-1 (8).
Because of the potency of LPV/r, lack of CD4 count-dependent
toxicity, and favorable tolerability profile in general, most treat-
ment guidelines of national, regional, and global organizations
and agencies (e.g., Department of Health and Human Services
perinatal guidelines, WHO, British HIV Association, and the Eu-
ropean AIDS Clinical Society) recommend LPV/r as a protease
inhibitor during pregnancy (3–7). Several clinical studies have
demonstrated LPV/r efficacy in achieving virologic suppression in
mothers during pregnancy and preventing HIV transmission to
their children (9–16). Reports of higher LPV clearance during
pregnancy have prompted some investigators to propose the use
of a higher dose during the third trimester, while others advocated
no adjustment to the standard 400/100-mg twice-daily (BID) reg-
imen (17–20). As an important component of cART given during
pregnancy, further assessment of LPV/r dosing during pregnancy
would support its appropriate use in this population. This analysis
employed a model-based approach to analyze LPV pharmacoki-
netics and pharmacodynamics in pregnant and nonpregnant
HIV-infected subjects to evaluate dosing of LPV/r in pregnant
women utilizing data collected in six studies.
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MATERIALS AND METHODS
Clinical studies and patient population. Six clinical studies of HIV-in-
fected adults were included in the analyses, three of whichwere conducted
with pregnant women and three of which were with nonpregnant sub-
jects. For each study, the study protocol was approved by the Institutional
Review Board of the individual study site, and written informed consent
was obtained from each subject prior to enrollment. All subjects were18
years of age and received cART regimens comprising two NRTIs plus
LPV/r (Table 1). All studies used validated high-performance liquid chro-
matography with tandem mass spectrometric detection (HPLC-MS/MS)
or UV detection (HPLC-UV) to quantitate LPV and RTV concentrations.
Table 1 summarizes the clinical studies used in this analysis and their
dosing and pharmacokinetic sampling schemes. Study 1 was a random-
ized, open-label prospective study that enrolled 53HIV-infected pregnant
womenbetween 14 and 30weeks of gestation (20). Subjects were random-
ized in a 1:1 ratio to receive LPV/r tablets either at 400/100 mg BID or
600/150mg BID during pregnancy; all participants then received LPV/r at
400/100 mg BID for at least 6 weeks postpartum. Pharmacokinetic evalu-
ations were performed at least 2 weeks after treatment initiation at the
following time points: second trimester (between 20 and 28 weeks of
gestation), third trimester (between 30 and 36 weeks of gestation), at
delivery, and postpartum (4 to 6 weeks after delivery), depending on the
gestational age at study enrollment.
Study 2 was a single-center, open-label study that compared the LPV
pharmacokinetics of tablet and soft gelatin capsule (SGC) formulations in
19 HIV-infected pregnant women (17). Throughout the study, subjects
received LPV/r at 400/100mg BID either as an SGC (cohort 1, n 8) or as
tablets (cohort 2, n 11). Pharmacokinetic evaluations were performed
in the second and third trimesters as well as 4 to 6 weeks after delivery.
Study 3 was a two-center, open-label study that compared the phar-
macokinetics of the LPV/r tablet at 400/100 mg BID and 500/125 mg BID
during the third trimester of pregnancy (21). The 500/125-mg dose was
achieved by adding a half-strength tablet of LPV/r of 100/25-mg to two
200/50-mg tablets. In this study, 12HIV-infected pregnantwomen receiv-
ing LPV/r at 400/100 mg BID underwent intensive LPV pharmacokinetic
analyses in the second trimester and at 30 weeks of gestation in the third
trimester. The LPV/r dose was increased in all women to 500/125 mg BID
after the week 30 pharmacokinetic visit, with subsequent pharmacoki-
netic sampling at 32 weeks of gestation. Two weeks after delivery, the
LPV/r dosewas decreased to 400/100mgBID, and pharmacokinetics were
reassessed 8 weeks after delivery.
Study 4 was an open-label, randomized phase 3 study comparing the
pharmacokinetics and pharmacodynamics of LPV/r at 800/200 mg once
daily (QD) and 400/100 mg BID in 664 treatment-naive HIV-infected
male andnonpregnant female subjects receiving the LPV/r tablet and SGC
formulations (22) Data from 316 subjects receiving the 400/100-mg BID
regimen were included in this analysis.
Study 5 was a randomized, open-label phase 3 study comparing the
pharmacokinetics and pharmacodynamics of LPV/r tablets at 800/200mg
QD and 400/100 mg BID in 599 treatment-experienced HIV-infected
male and nonpregnant female subjects (23). Data from 261 subjects re-
ceiving the 400/100-mg BID regimen were included in this analysis.
Study 6 was a randomized, double-blind, multicenter phase 1/2 study
of LPV/r soft gelatin capsules BID in 100HIV-infectedmale and nonpreg-
nant female subjects without prior antiretroviral therapy (24). Data from
18 subjects receiving 400/100-mgBIDdoseswere included in this analysis.
Population pharmacokinetic analysis. Concentration-time data
were pooled across all studies and analyzed using a nonlinear mixed-
effects population analysis approach with NONMEM (version 7.3.0) (25,
26). The first-order conditional estimation (FOCE) method with eta-ep-
silon (-ε) interaction was employed throughout the model develop-
ment. The graphic processing of the NONMEM output was performed
with SAS (version 9.4).
Population pharmacokinetic models were built for LPV using total
plasma concentrations. After dose proportionality was established, both
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one- and two-compartmentmodels with first-order absorption and elim-
ination (ADVAN 2 and ADVAN 3 subroutines in NONMEM) were fitted
to the data. Both a proportional plus additive-error model and propor-
tional residual-error model were assessed. Individual pharmacokinetic
parameters were assumed to be log-normally distributed, and the inter-
individual variability in pharmacokinetic parameters was modeled using
an exponential error model.
Two approaches were attempted to describe the RTV inhibition of
LPV clearance. First, RTV inhibition of LPV clearance was modeled
using a competitive inhibition model according to the following equa-
tion (27): CL  TVCL  RTVConc/[1  (RTVConc/Ki)], where CL is
clearance, TVCL is the typical value for LPV clearance in the absence of
RTV, RTVConc is the observed RTV concentration, and Ki is the inhi-
bition constant.
Second, RTV inhibition of LPV clearance was modeled using a maxi-
mum-inhibition model according to the following equation (28): CL 
TVCL  [1  RTVConc/(IC50  RTVConc)], where IC50 represents the
RTV concentration at which a half-maximal inhibition effect on LPV
clearance is obtained.
Covariate modeling was performed using the forward-inclusion (P
0.05), backward-elimination (P  0.001) approach and was guided by
evaluation of the empirical Bayesian pharmacokinetic parameter esti-
mates versus covariate plots as well as changes in the estimates of phar-
macokinetic parameter variability and residual variability. Nestedmodels
were compared using a likelihood ratio test, while nonnestedmodels were
compared using the Akaike information criterion.
Precision of the final model parameter estimates was assessed using
the asymptotic standard errors obtained by the covariance routine in
NONMEM as well as by the bootstrap confidence intervals. In boot-
strapping, subjects were randomly sampled with replacement from the
data set that was used in model development to obtain 1,000 data sets
that have the same number of subjects as the original data set. The final
model was then fitted to each of these data sets, and the parameter
estimates were compared to the estimates from the original data set.
The final model was qualified by visual predictive check where the final
parameter estimates were used to simulate 1,000 replicates of the ob-
served data set. The median and 5th and 95th percentile concentra-
tions of the simulated data sets were then plotted against the original
observations.
Statistical analysis. To establish the pharmacokinetic comparabil-
ity of LPV between nonpregnant subjects and pregnant women, the
linear mixed-model methodology using PROC MIXED in SAS system
software, version 9.4, was used to compare the area under the concen-
tration-time curve from 0 to 12 h (AUC0–12) and concentration prior
to dosing (Cpredose) in pregnant women receiving the tablet formula-
tion in their second and third trimesters and nonpregnant subjects
receiving the SGC formulation. To assess statistical differences be-
tween the dose groups across studies, the differences in means were
estimated with the corresponding least-squares means obtained from
the mixed model on the logarithm of AUC0–12 and Cpredose. Corre-
sponding P values for the comparisons were estimated.
Exposure-virologic response relationship. LPV exposure-response
relationships in pregnant women were explored using both scatter plots
and quartile plots. In scatter plots, LPV AUC0–12 and Cpredose values in
pregnant women were plotted against HIV-1 viral load collected at the
same visit. Furthermore, the percentage of subjects with viral load less
than 50 copies per ml (percent responders) was compared across the four
quartiles of LPV AUC0–12 and Cpredose values in both pregnant women
and nonpregnant subjects. Bayesian post hoc estimates obtained from the
population pharmacokinetic model were used to obtain AUC0–12 and
Cpredose values for subjects with sparse pharmacokinetic sampling. For all
other subjects, observed AUC0–12 and Cpredose values were used in the
analysis.
RESULTS
Population pharmacokinetic analysis. The analysis included
3,079 total LPV plasma concentrations and 3,077 total RTV
plasma concentrations from 84 pregnant women and 595 non-
pregnant subjects.
A one-compartment disposition model with first-order ab-
sorption and elimination best described the LPV plasma concen-
tration-time data. A lag time describing a potential absorption
delay was not observed in the majority of subjects and hence was
not added to the model. Both the competitive inhibition and the
maximum effect (Emax)-type inhibition models for evaluating the
effect of RTVonLPV clearancewere supported by the data and led
to similar results. It was decided to move forward with the Emax-
type inhibition model on clearance as the interpretation of the
IC50 term allowed comparison of the estimates to results of other
studies that used the same approach.
The data supported including interindividual variability terms
for apparent clearance and apparent central volume of distribu-
tion, which were estimated with high precision. The correlation
between CL/F and Vc/F (Vc is the apparent central volume of dis-
tribution) was estimated to be 0.23 in the basemodel. Inclusion of
interindividual variability terms for the absorption rate constant
and IC50 was attempted. These terms were associated with high
shrinkage of greater than 50% and hence were not added to the
model. The residual unexplained variability was best character-
ized using a combined-additive and proportional-errormodel be-
cause both additive and proportional residual-error models pro-
vided inferior fits.
The final model parameter estimates and the precision associ-
ated with their estimations are shown in Table 2. Both fixed and
randomeffectswere precisely estimatedwith percent relative stan-
dard error (RSE) of 16% or less. Accounting for the difference in
bioavailability levels between the tablet and SGC formulationswas
found to significantly improve the fit; the bioavailability of the
tablet formulationwas estimated to be 20%higher than that of the
SGC formulation in the final model. Pregnancy status was also
found to be a significant predictor of LPV clearance. Both the
second and third trimesters had similar increases of 17% in clear-
ance; postpartum women had a decrease of 26.4% in clearance
compared with that of nonpregnant subjects.
Finally, body weight was found to be a significant covariate on
apparent volume of distribution but not on LPV clearance. The
need for estimating the exponent of the allometricmodel for body
weight on volume of distribution was tested to ensure model par-
simony. Fixing the exponents to 1 resulted in a nonsignificant
increase in the objective function value (OFV) (P value 0.156),
and hence estimating the exponent was deemed unnecessary and
was kept fixed at 1 in themodel, which indicates that an increase in
body weight is predicted to be associated with a proportional in-
crease in volume of distribution.
Lopinavir apparent clearance population estimates were 6.62,
7.75, and 4.87 liters/h in nonpregnant adults, pregnant women,
and postpartumwomen, respectively. The lopinavir apparent vol-
ume of distribution population estimate was 63.7 liters, with no
differences between nonpregnant adults and pregnant and post-
partum women.
The final equations and typical values of LPV parameters were
as follows. Bioavailability was 1.2 for the tablet and 1 for the
SGC. Clearance was equal to 6.62Trimester (1 RTVConc)/
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(0.239  RTVConc), where  is 1.17 for the second or third
trimester of pregnancy, 0.736 for the postpartum subjects, and
1 for nonpregnant subjects. The volume of distribution was
calculated as 63.7  (WTKG/71), where WTKG is weight in
kilograms.
In order to confirm the stability of the model precision of esti-
mated pharmacokinetic parameters, a nonparametric bootstrap
analysis was performed, and 96.4% of the bootstrap replicates
converged successfully. In accordancewith the estimated standard
errors of estimates for pharmacokinetic parameters in the LPV
pharmacokineticmodel, the bootstrap showednarrow confidence
intervals for all parameters. The medians and 5th and 95th per-
centiles of the parameter estimates from the fit of the final model
to the bootstrap samples are shown in Table 2. The asymptotic
estimates obtained from the original data set showed close agree-
mentwith themedian andwere all includedwithin the 2.5th to the
97.5th percentiles of the bootstrapping values, indicating model
stability. None of the 95% confidence intervals for the parameters
from the bootstrap data sets included zero, confirming the robust-
ness of parameters.
For the visual predictive checks, observed plasma concentra-
tion-time data, and 5th, 50th, and 95th percentiles of observed
data and confidence intervals of the 5th, 50th, and 95th percentiles
of simulated data are shown in Fig. 1, indicating sufficient predic-
tive ability of the model to describe LPV concentrations.
Statistical analysis. There were no statistically significant dif-
ferences in mean LPV AUC0–12 and Cpredose values between preg-
nant women in the second trimester receiving the LPV/r tablet
and nonpregnant subjects receiving the SGC formulation at the
400/100-mg BID dose (P values of 0.66 and 0.21, respectively).
Furthermore, there were no statistically significant differences in
LPV AUC0–12 or Cpredose values between women in the third tri-
mester receiving 400/100-mg tablets BID and nonpregnant HIV-
infected subjects receiving the LPV/r SGC formulation at the 400/
100-mg BID dose (P values of 0.83 and 0.25, respectively). A
comparison of the LPV AUC0–12 and Cpredose values in pregnant
women during second and third trimesters receiving the tablet
formulation at different doses and nonpregnant subjects re-
ceiving the SGC formulation at the 400/100-mg BID dose is
shown in Fig. 2.
Exposure-virologic response relationship. Figure 3 shows the
relationship between individual LPV AUC0–12 and Cpredose values
achieved in the third trimester andHIV-1 virologic responsemea-
sured as plasmaHIV-1 RNA levels (copies/ml). Substantial reduc-
tions in HIV-1 RNA were achieved by the third trimester for all
doses of LPV/r administered. In the range of LPV AUC0–12 or
Cpredose values observed in the third trimester, there does not ap-
pear to be a relationship between observed exposure and plasma
HIV-1 RNA levels.
Of the 84 pregnant women included in this analysis, 21/22
(95.5%) treatment-experienced and 57/62 (91.9%) treatment-
naive subjects had plasmaHIV-1RNA levels of less than 50 copies/
ml. Only one treatment-experienced pregnant woman receiving
400/100-mg BID SGC had an observed HIV-1 RNA level greater
than 400 copies/ml during the third trimester. Five treatment-
naive pregnant women had an observed plasmaHIV-1 RNA level
between 50 and 400 copies/ml, with three receiving LPV/r SGC
at 400/100 mg BID and two receiving an LPV/r tablet at 400/
100 mg BID.
Quartile plots of the percentage of subjects with viral loads of
less than 50 copies/ml stratified byCpredose andAUC0–12 values are
shown in Fig. 4. While a lower response rate was observed in
pregnant women in the lowest quartile, the response rates were
similar between this quartile and those of nonpregnant adults
across all quartiles.
DISCUSSION
We evaluated the pharmacokinetic differences between pregnant
women and nonpregnant subjects using nonlinear mixed-effect
analysis of LPV and RTV plasma concentrations pooled from
studies of both populations. The final model estimates for LPV
clearance and volume of distribution in nonpregnant subjects
were similar to those of previously published pharmacokinetic
studies (27, 28). RTV concentrations increased LPV concentra-
tions, with an IC50 of 0.239	g/ml in thismodel, which reflects the
potency of the RTV inhibitory effect on LPV clearance and is
consistent with prior estimates (29, 30). The model was qualified
using both bootstrapping and visual predictive checks.
The final population pharmacokinetic model estimated LPV
clearance to be 17% higher in pregnant women during their sec-
ond and third trimesters than in nonpregnant subjects. This in-
crease in clearance is consistent with the induction of hepatic
TABLE 2 Population pharmacokinetic parameter estimates obtained after fitting the final model to the original data set and to 1,000 bootstrap
samplesa
Parameter
Model result Bootstrap result
Population estimate (SEE)b
%
RSEc Mean Median 95% confidence interval
Volume of distribution (liters) 63.70 (3.2) 5.0 63.44 63.3 57.50–69.90
Clearance (liters/h) 6.62 (0.26) 3.8 6.70 6.64 5.980–7.770
Absorption rate constant (1/h) 0.712 (0.03) 4.3 0.73 0.721 0.551–0.940
Pregnancy on CL 1.17 (0.03) 2.6 1.19 1.18 1.030–1.390
Postpartum on CL 0.736 (0.02) 2.7 0.74 0.735 0.646–0.837
IC50 (	g/ml) 0.239 (0.01) 4.3 0.24 0.235 0.131–0.373
Tablet on bioavailability 1.200 (0.05) 4.0 1.19 1.190 1.110–1.290
Interindividual variance of volume of distribution 0.183 (0.03) 16.0 0.19 0.189 0.112–0.280
Interindividual variance of clearance 0.130 (0.01) 6.6 0.13 0.131 0.101–0.166
a Based on 964/1,000 successful runs.
b SEE, standard error of the estimate.
c RSE, relative standard error.
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CYP3A and P-glycoprotein (P-gp) activity during pregnancy (31,
32). The model also estimated the tablet formulation to be 20%
more bioavailable than the SGC formulation in both pregnant
women and nonpregnant subjects. The increase in bioavailability
is consistent with that observed in a bioequivalence study of
healthy volunteers, where the LPV/r tablet formulation demon-
strated 18 to 24%higher bioavailability than the SGC formulation
under fed conditions (33). This indicates that despite the increase
in clearance during pregnancy, the bioavailability of the tablet
formulation may compensate for the increased clearance, and
thus pregnant women receiving the tablet formulation still main-
tain LPV exposure that is similar to the efficacious exposure in
FIG 1 Visual predictive check for the final model. Circles represent the medians, and error bars represent the 5th and 95th percentiles of observations. Shaded
areas represent 95% confidence intervals of the 5th, 50th, and 95th percentiles of simulated data.
FIG 2 Box plots of LPV AUC0–12 and Cpredose values in nonpregnant subjects and pregnant women in the second (T2) and third (T3) trimesters. Values for the
25th to the 75th percentile of exposure are boxed, the horizontal line represents the median, and the symbol in the box represents the mean. Whiskers represent
the 5th to 95th percentiles of exposure, and additional symbols outside the box represent the outlying data.
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FIG 3 HIV-1 RNA response versus LPV AUC0–12 and Cpredose values in the third trimester of pregnancy. LOQ, limit of quantitation.
FIG 4 Quartile plots of the percentages of HIV-1 RNA responders stratified by LPV exposure in pregnant women (third trimester) and nonpregnant subjects.
The exposure range in each quartile is shown in parentheses on the x axis. Each error bar represents the 90% confidence interval of the percentage of responders
based on binomial distribution. ARV, antiretroviral therapy.
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nonpregnant subjects receiving the SGC formulation. Statistical
analysis confirmed the similarity in LPV AUC0–12 and Cpredose
values between the pregnant and nonpregnant populations.
The results of our population pharmacokinetic analysis esti-
mated LPV clearance postpartum to be 26.4% and 37.1% lower
than the clearance in nonpregnant subjects and pregnant women,
respectively. A recent study estimated a similar magnitude of
higher CYP3A4 activity in pregnant women (35%) than in post-
partum subjects as measured by the urinary ratio of 6-
-hydroxy-
cortisol to cortisol as a marker (34). Several other studies investi-
gating the pharmacokinetics of LPV/r tablets in pregnant women
similarly reported LPV exposure during the third trimester with
the 400/100-mg BID tablet dose to be 35% to 45% lower than the
postpartum exposure (18, 35–40). Other clinical studies evaluated
LPV pharmacokinetics for the SGC formulation in pregnant
women (19, 41, 42). Similar to the results with the LPV/r tablet
formulation, following administration of LPV/r as 400/100-mg
SGC BID, LPV exposure in the third trimester was approximately
30% lower than the exposure observed 2 weeks after delivery.
It is important to note that the LPVCpredose was above 1	g/ml
in most of the pregnant women receiving 400/100 mg BID of
either the LPV/r tablet or SGC formulation. This plasma LPV
trough target is approximately 15 times the protein binding-ad-
justed plasma concentration required to obtain 50% of the maxi-
mum effect in vivo (EC50) for the wild-type HIV-1 (43–46).
We assessed virologic suppression in pregnant women receiv-
ing LPV/r during pregnancy. Virologic suppression was main-
tained in the vastmajority of the pregnant women included in this
analysis. As most of the subjects in these studies initiated treat-
ment during their pregnancy, it is not unexpected that some sub-
jects would not be fully suppressed with a treatment duration of
less than 26 weeks, even when adequate plasma LPV levels are
achieved. Overall, quartile plots of the percentage of subjects with
virologic suppression versus LPV AUC0–12 and Cpredose values in
pregnant women showed response rates comparable to, if not
higher than, those of nonpregnant subjects with similar or longer
treatment durations.
We also explored the relationship between LPV exposure and
the proportion of subjects with virologic suppression. There was
no correlation between the HIV-1 RNA virologic response and
LPV exposures achieved in pregnant women or nonpregnant sub-
jects, with similar response rates achieved in all four quartiles of
AUC0–12 and Cpredose values. The high response rate leading to a
lack of exposure response correlation limited the ability to model
the relationship between lopinavir concentrations and the viral
load. In addition, a similarHIV-1RNAvirologic response ratewas
achieved in both ART-naive and ART-experienced women in
their third trimesters of pregnancy. There are insufficient data to
recommend dosing in pregnant women with any documented
lopinavir-associated resistance substitutions.
LPV is highly protein bound to plasma proteins with higher
affinity to alpha-1 acid glycoprotein (AAG) than to albumin. Con-
flicting reports on the fraction of LPV unbound during pregnancy
have been reported. One study demonstrated no change in the
fraction of LPV unbound, and four studies reported an increase in
the fraction of LPV unbound (16, 20, 28, 47, 48). An increase in
the fraction unbound may potentially offset at least part of the
increase of the LPV clearance during pregnancy. Aweeka et al.
reported an 18%higher LPV unbound fraction in the plasma dur-
ing the third trimester than at postpartum (n  28) (49). This
higher LPV unbound fraction was associated with 52% and 15%
reductions in AAG and albumin concentrations, respectively.
Kiser et al. reported 40% and 50% higher LPV unbound fractions
in the plasma during the second and third trimesters, respectively,
than at postpartum (n  9) (47). More recently, Else et al. re-
ported that the LPVunbound fractionwas 27%and 17%higher in
the second and third trimesters, respectively, than at postpartum
(n 11) (17). Lastly, Fayet-Mello et al. reported an increase of 7%
to 29% in the LPV unbound fraction and a decrease in AAG and
albumin during pregnancy (38). The increase in the unbound
fraction may be explained by displacement of LPV from binding
sites by steroid and placental hormones and dilutional decreases
in albumin and AAG concentrations (39, 48, 50, 51).
A systematic review has recently assessed the effects of LPV/r
on maternal and infant clinical and safety outcomes in HIV-in-
fected pregnant women (52). Nine studies were identified, com-
prising 2,675 LPV/r-treated women. The results from this system-
atic review suggested no unique safety or efficacy concerns with
use of the standard dose LPV/r as part of cART in pregnant
women. Furthermore, in 1,333 and 2,371 women exposed to
LPV/r in the first and second/third trimesters, respectively, in the
French perinatal cohort, no association was found between birth
defects and LPV or RTV (53). As of January 2013, the Antiretro-
viral Pregnancy Registry has cumulatively received prospective
reports of 3,335 exposures to LPV/r-containing regimens. Birth
defects occurred in 24 of the 1,049 (2.3%) live births with first
trimester exposure and in 67 of the 2,286 (2.9%) live births with
second/third trimester exposure (54). The prevalence of congen-
ital birth defects among the offspring of women with first- and
second/third-trimester LPV/r exposures was not significantly dif-
ferent from the prevalence of congenital birth defects in offspring
of pregnant women in the United States reference population,
whose background rate of birth defects is 2.7%. No pattern of
birth defect signal was detected for LPV/r (54).
In conclusion, dosing recommendations for antiretroviral
agents in HIV-infected, pregnant women should be based on
the assessment of the pharmacokinetic exposures and virologic
response during pregnancy, rather than from exposure com-
parison with nonpregnant subjects or postpartum measure-
ments (i.e., the initial weeks after delivery). For LPV, nonlinear
mixed-effects modeling as utilized in our analysis is the most
appropriate approach to make this evaluation since it can ac-
count for inter- and intrasubject variability between pregnant
women and nonpregnant subjects. Although the LPV exposure
in the third trimester of pregnancy was lower than that of non-
pregnant subjects receiving the same formulation or in the
postpartum period, the increase in LPV clearance during preg-
nancy is compensated by the higher bioavailability of the LPV/r
tablet formulation than that of the SGC formulation along with
potentially a decrease in protein binding. Over 90% of the
pregnant women in this analysis were virologically suppressed.
Analysis of virologic response in pregnant women receiving
400/100 mg of LPV/r BID demonstrated no association with
LPV exposure and no difference compared with responses of
nonpregnant subjects, which is consistent with demonstration
of LPV plasma trough concentrations above 1 	g/ml. The vi-
rologic response is also consistent with the demonstrated effi-
cacy in both treatment-naive and treatment-experienced HIV
subjects of the original SGC formulation of LPV/r (21, 55),
which has lower LPV exposure than the tablet formulation.
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Pregnant women achieved virologic suppression with the 400/
100-mg twice-daily regimen of LPV/r tablets, and there has
been no signal of increased rate of congenital birth defects seen
in their offspring. Based on our pharmacokinetic and pharma-
codynamic evaluation, LPV/r tablets in doses of 400/100 mg
twice daily during pregnancy is appropriate, and no dosage
adjustment for LPV/r is recommended.
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